VIVI Cap Smart transforms injectable medication protection into a connected health-data layer, enabling patients, caregivers ...

Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous ...

ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET. Orion Pharma announces first patient dosed in Phase 1/2 ...

(NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance ...

Multi-year expansion of the companies’ 2025 agreement to use Gate’s Molecular Gate drug discovery engine to design molecular ...

Vasomune's lead therapy targeting vascular leak, for dual-use applications. TORONTO--(BUSINESS WIRE)--#ARDS--Vasomun ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Through BIO REBOOT, individuals and teams can bring research questions, technical expertise and drug discovery ideas to the ...

VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ...

All signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin ...

(“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the ...

Next generation continuous direct compression (CDC) platform, jointly developed with GEA, to bring a continuous tableting ...